SARS-CoV-2 IgG Antibody (COVID-19)

Laboratory Bulletin

Effective Date: May 11, 2020

On May 11, 2020 Beaumont Laboratory will start to perform testing for SARS-CoV-2 IgG antibody on the Abbott Architect immunoassay platform. The Laboratory has independently validated the test using serum from patients known to have been either positive or negative by molecular testing and the assay is now approved by the FDA under an Emergency Use Authorization (EUA). The clinical utility of the test and ordering information is provided below.

Clinical Utility

- IgG antibodies to SARS-CoV-2 are detected in the majority of individuals approximately two weeks after the onset of COVID-19 symptoms. If a specimen is collected too early (i.e. prior to seroconversion), the test will yield a negative result.
- Presence of IgG antibodies indicates a previous exposure to SARS-CoV-2 and is a measure of immunological responsiveness. However, it is not known at this time if the presence of antibodies confers protective immunity against the virus.
- The SARS-CoV-2 IgG assay is not a diagnostic test. Direct viral detection assays that employ molecular methods such as nucleic acid amplification, are the only laboratory tests that are diagnostic for COVID-19.
- IgG results should not be used to make decisions on infection status

Ordering Information

- Soft = CVIG2
- Epic code for SOFT = LAB7955
- Sunquest = CVIGG2
- Epic code for Sunquest = LAB03876
- CPT code = 86769
- LOINC = 94507-1

If you have questions, please contact your Client Services Department:

- Farmington Hills, Grosse Pointe, Royal Oak and Troy: 1-800-551-0488; Option 5
- Dearborn, Taylor, Trenton and Wayne: 1-800-245-3725; Option 1

Date submitted: April 27, 2020

Submitted By: Katie (Qian) Sun, PhD, Technical Director, Automated Chemistry Core Lab, RO
Gabriel Maine, PhD, Technical Director, Special Chemistry, RO
Elizabeth Sykes, MD, System Medical Director, Clinical Chemistry